RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025
RenovoRx, Inc. (“RenovoRx” or the “Company”), a pioneering life sciences company dedicated to advancing targeted oncology therapies, is pleased to announce that its research supporting the Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform has been recognized as an award-winning paper. The findings, published in the Journal of Vascular and Interventional Radiology (JVIR), will be honored during the prestigious JVIR Award-Winning Paper Scientific Session at the Society of Interventional Radiology (SIR) 2025 Annual Scientific Meeting.
This esteemed recognition is a testament to RenovoRx’s commitment to innovation in the field of interventional oncology. The paper, first published in the July 2024 edition of JVIR, will be presented at the JVIR Award-Winning Paper Scientific Session in Nashville, Tennessee, on Tuesday, April 1, 2025, from 3:00 to 4:30 PM CT. This session will be moderated by Dr. Daniel Sze, MD, PhD, from Stanford University and will highlight groundbreaking research in interventional radiology. RenovoRx’s paper is one of nine JVIR papers to receive this prestigious recognition for outstanding laboratory investigation.
Groundbreaking Research in Targeted Drug Delivery
The awarded paper, titled “Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model: A Mechanism Recruiting the Vasa Vasorum for Localized Therapies,” was authored by Khashayar Farsad, MD, PhD, from the Department of Interventional Radiology at Oregon Health and Science University. Dr. Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, along with a team of researchers, including RenovoRx’s founder and Chief Medical Officer, Dr. Ramtin Agah, co-authored the paper.
Dr. Agah will present the paper’s findings during the session, showcasing the potential of RenovoRx’s TAMP platform to revolutionize targeted chemotherapy delivery. The full abstract is available on PubMed at this link.
Implications of TAMP Therapy in Oncology
Currently, patients diagnosed with solid tumors receive chemotherapy intravenously, which leads to systemic drug distribution throughout the body. This widespread drug exposure often results in severe adverse effects, including toxicity to healthy tissues and organs. To address these challenges, RenovoRx has developed its proprietary TAMP therapy platform, designed to bypass traditional systemic delivery methods and precisely administer chemotherapy directly to solid tumors. By doing so, TAMP aims to enhance therapeutic efficacy while reducing systemic toxicity.
Pre-clinical studies published in JVIR demonstrated that the TAMP platform delivers a remarkable 100-fold (two orders of magnitude) increase in local tissue concentration of chemotherapy drugs compared to conventional intravenous (IV) administration. Furthermore, TAMP has demonstrated superior effectiveness compared to historically available intra-arterial (IA) drug delivery methods. This innovative approach offers a paradigm shift in oncology treatment by enabling more uniform drug distribution within targeted tumor tissues.
Expert Perspectives on the Impact of TAMP
Dr. Agah expressed his gratitude for the recognition at SIR 2025, emphasizing the significance of RenovoRx’s advancements in interventional oncology. “We are deeply honored to be acknowledged for our research at the JVIR Award-Winning Paper Scientific Session,” he stated. “This recognition underscores RenovoRx’s dedication to pioneering a new treatment paradigm that has the potential to benefit patients suffering from solid tumors. I look forward to presenting these findings at the upcoming conference, and my colleagues and I are immensely grateful for this validation of our commitment to innovation in oncology.”
Dr. Khashayar Farsad, lead author of the paper, also highlighted the transformative potential of TAMP. “This platform presents a valuable treatment option for patients with solid tumors that have been traditionally difficult to treat,” he remarked. “Moreover, TAMP has the potential to be applied across various unmet needs in localized therapeutic drug delivery. Our study reveals a novel mechanism by which TAMP increases local drug concentration in tumor tissues, independent of conventional catheter-based therapies. We eagerly await final outcomes from RenovoRx’s ongoing TIGeR-PaC Phase III clinical trial, which will further validate these benefits.”
Accelerating Commercialization and Future Outlook
RenovoRx remains committed to expanding the commercialization of its proprietary RenovoCath® as a standalone device while continuing its clinical advancements. CEO Shaun Bagai emphasized the company’s strategic growth plans: “We believe this award further reinforces our decision to accelerate the commercialization of RenovoCath. We are rapidly expanding our efforts and strengthening relationships with leading oncology centers nationwide that are adopting our device. This progress not only positions RenovoRx for significant growth but also solidifies our leadership in the field of interventional oncology.”
RenovoRx continues to scale its commercialization strategy while simultaneously advancing its Phase III TIGeR-PaC trial. This approach ensures the most efficient allocation of resources while maximizing the company’s impact in oncology. By integrating its proprietary drug delivery technologies with established interventional radiology techniques, RenovoRx is poised to redefine cancer treatment and improve outcomes for patients with challenging solid tumors.
